. 2006 Dec 20;35(4):e21. doi: 10.1093/nar/gkl917

Table 1.

Strains and plasmids used in this study

Bacterial strains
JM109	e14^–(McrA^–) recA1 endA1 gyrA96 thi-1 hsdR17 ( $r_{K}^{-}$ $m_{K}^{+}$ ) supE44 relA1 Δ(lac-proAB) [F' traD36 proAB lacI^qZΔM15]	Laboratory stock

BL21 star™(DE3)	F^– ompT hsdS_B( $r_{B}^{-}$ $m_{B}^{-}$ ) gal dcm rne131	Invitrogen
Plasmids^a
pIVEX2.3d	Ampicillin resistant, C-terminal His-tag	Roche Applied Sciences
pK7hEPO	EPO (501 bp) cloned into NdeI/SalI sites	(18)
pK7pelBss-EPO	pK7EPO derivative containing the signal peptide sequence of pelB (66 bp)	This study
pK7ompAss-EPO	pK7EPO derivative containing the signal peptide sequence of ompA (63 bp)	This study
pK7phoAss-EPO	pK7EPO derivative containing the signal peptide sequence of phoA (63 bp)	This study
pK7malEss-EPO	pK7EPO derivative containing the signal peptide sequence of malE (78 bp)	This study
pK7ompCss-EPO	pK7EPO derivative containing the signal peptide sequence of ompC (63 bp)	This study
pK7ompTss-EPO	pK7EPO derivative containing the signal peptide sequence of ompT (60 bp)	This study
pK7heposs-EPO	pK7EPO derivative containing the signal peptide sequence of human EPO (81 bp)	This study

^aAll the pK7 plasmids have kanamycin resistance and the same 5′-UTR sequences including T7 promoter and RBS.